Key Takeaways:
- Expert comments from Martine Zimmermann, Ipsen’s head of regulatory and R&D quality, on improving the development and approval process for rare disease therapies, particularly in the pediatric setting.
It has been 40 years since the US passed the Orphan Drug Act 1983, which introduced financial incentives for the biopharma sector to develop treatments for rare diseases, from longer market exclusivity to R&D tax credits. While hundreds of therapies have since been approved, most rare diseases still lack treatment options.
The therapeutic space has presented a unique challenge due to the complex underlying biology and lack of understanding of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?